Zevra Therapeutics, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Zevra Therapeutics, Inc. (ZVRA) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $2.31 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-12.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2021-03-12
- Zevra Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2019-09-30 was $2.31M.
- Zevra Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2019 was $2.31M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|
| 2019-12-31 | $2.31M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $2.31M 10-Q · filed 2020-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |